Статья
Клинические рекомендации по диагностике и лечению фибрилляции предсердий (2020): что нового для невролога?
Клинические рекомендации по диагностике и лечению пациентов с фибрилляцией предсердий (ФП) являются одним из наиболее регулярно обновляемых документов, публикуемых под эгидой Европейского общества кардиологов. Новая версия клинических рекомендаций (2020) содержит в себе ряд изменений касательно проведения антикоагулянтной терапии у пациентов с ФП, у которых развилось острое нарушение мозгового кровообращения. В настоящем обзоре обсуждаются положения обновленного документа, посвященные срокам старта/рестарта антикоагулянтной терапии после перенесенных ишемического инсульта и внутричерепного кровоизлияния у пациентов с ФП, вопросу выбора антитромботической терапии у пациентов с криптогенным инсультом и необходимости дополнительного обследования данной группы пациентов для уточнения источника эмболии. Авторами обозначена позиция относительно возможности применения данных рекомендаций в реальной клинической практике с позиции баланса между персонифицированным подходом лечения пациента и стратифицированным принципом выбора оптимальных сроков старта/рестарта терапии антикоагулянтами у пациентов неврологического профиля.
1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1-e88. doi:10.1093/ejcts/ezw313
2. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020; ehaa612. doi:10.1093/eurheartj/ehaa612
3. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39(8):2249–2256. doi:10.1161/STROKEAHA.107.510321
4. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38(2):423–430. doi:10.1161/01.STR.0000254600.92975.1f
5. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–651. doi:10.1093/europace/eut083
6. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10): 1360–1420. doi:10.1093/europace/euq350
7. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF Study. Stroke. 2015; 46(8):2175–2182. doi:10.1161/STROKEAHA.115.008891
8. Arihiro S, Todo K, Koga M, Furui E, Kinoshita N, Kimura K et al. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) Study. Int J Stroke. 2016;11(5):565–574. doi:10.1177/1747493016632239
9. Wilson D, Ambler G, Banerjee G, Shakeshaft C, Cohen H, Yousry TA et al. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. J Neurol Neurosurg Psychiatry. 2019;90(3):320–325. doi:10.1136/jnnp-2018–318890
10. Alrohimi A, Ng K, Dowlatshahi D, Buck B, Stotts G, Thirunavukkarasu S et al. Early dabigatran treatment after transient ischemic attack and minor ischemic stroke does not result in hemorrhagic transformation. Can J Neurol Sci. 2020;47(5):604–611. doi:10.1017/cjn.2020.84
11. Hong KS, Kwon SU, Lee SH, Lee JS, Kim YJ, Song TJ et al. Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke: a Randomized Clinical Trial. JAMA Neurol. 2017;74(10):1206–1215. doi:10.1001/jamaneurol.2017.2161
12. Seiffge DJ, Werring DJ, Paciaroni M, Dawson J, Warach S, Milling TJ et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117–126. doi:10.1016/S1474-4422(18)30356-9
13. Weber R, Brenck J, Diener HC. Antiplatelet therapy in cerebrovascular disorders. Handb Exp Pharmacol. 2012;(210):519– 546. doi:10.1007/978-3-642-29423-5_21
14. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004;(4): CD 000187. Published. 2004. doi:10.1002/14651858.CD000187.pub2
15. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–2078. doi:10.1056/NEJMoa0901301
16. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429– 438. doi:10.1016/S1474-4422(13)70310-7
17. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017;48(4):867–872. doi:10.1161/STROKEAHA.116.016414
18. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–2486. doi:10.1056/NEJMoa1313600
19. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906– 1917. doi:10.1056/NEJMoa1813959
20. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191– 2201. doi:10.1056/NEJMoa1802686
21. Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nägele T et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke. 2017;12(9):985–990. doi:10.1177/1747493016681019
22. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2019;76(7):764–773. doi:10.1001/jamaneurol.2019.0617
23. Elkind M. ARCADIA: predicting risk for atrial cardiopathy poststroke. Available from: https://www.medscape.comviewarticle/925471#vp_2.
24. Akoum N. Atrial fibrosis predicts recurrent stroke or new atrial fibrillation in patients with embolic stroke of undetermined source — a multi-center study. Available from: https://www.dicardiology.com/content/atrial-fibrosis-predicts-recurrent-strokeor-new-af-onset%C2%A0
25. Li YG, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B et al. C 2HEST score and prediction of incident atrial fibrillation in poststroke patients: a French Nationwide Study. J Am Heart Assoc. 2019;8(13): e012546. doi:10.1161/JAHA.119.012546
26. Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality and bleeding: a Nationwide Cohort Study. Circulation. 2015;132(6):517–525. doi:10.1161/CIRCULATIONAHA.115.015735
27. Yung D, Kapral MK, Asllani E, Fang J, Lee DS; Investigators of the Registry of the Canadian Stroke Network. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the best practice for reinitiating anticoagulation therapy after intracranial bleeding (BRAIN) study. Can J Cardiol. 2012;28(1):33–39. doi:10.1016/j.cjca.2011.10.002
28. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34(7):1710–1716. doi:10.1161/01.STR.0000078311.18928.16
29. van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJE, van Gelder IC et al. Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulationassociated intra cerebral haemorrhage in patients with atrial fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials. 2015;16:393. doi:10.1186/s13063-0150898-4
30. Al-Shahi Salman R, Dennis MS, Murray GD, Innes K, Drever J, Dinsmore L et al. The REstart or STopAntithromboticsRandomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. Trials. 2018;19(1):162. doi:10.1186/s13063-018-2542-6
31. Charidimou A, Imaizumi T, Moulin S, Biffi A, Samarasekera N, Yakushiji Y et al. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis. Neurology. 2017;89(8):820–829. doi:10.1212/WNL.0000000000004259
32. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-0
33. Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME et al. Comparative stroke, bleeding and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596–604. e11. doi:10.1016/j.amjmed.2018.12.023
34. Hemphill JC, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a Guideline for Healthcare Professionals from the American Heart Association / American Stroke Association. Stroke. 2015;46(7):2032–2060. doi:10.1161/STR.0000000000000069